262 related articles for article (PubMed ID: 36950962)
21. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
22. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
Abramson JS
Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848
[TBL] [Abstract][Full Text] [Related]
23. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
25. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
26. [Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia].
Song FM; Hu YX; Zhang MM; Wu WW; Xu HJ; Zhang HS; Huang H; Wei GQ
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):651-656. PubMed ID: 36709149
[No Abstract] [Full Text] [Related]
27. Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?
Bouziana S; Bouzianas D
Biol Blood Marrow Transplant; 2020 Aug; 26(8):e183-e191. PubMed ID: 32304874
[TBL] [Abstract][Full Text] [Related]
28. Emerging Role of Autologous CD19 CAR T-Cell Therapies in the Second-Line Setting for Large B-cell Lymphoma: A Game Changer?
Mohty R; Moustafa MA; Aljurf M; Murthy H; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):73-80. PubMed ID: 36395495
[TBL] [Abstract][Full Text] [Related]
29. [Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
Beauvais D; Bachy E; Baruchel A; Bay JO; Caillot D; Cartron G; Damaj G; Furst S; Le Gouill S; Morschhauser F; Rabian F; Rubio MT; Thieblemont C; Yakoub-Agha I
Bull Cancer; 2021; 108(7-8):725-729. PubMed ID: 33423776
[TBL] [Abstract][Full Text] [Related]
30. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT).
Nahas GR; Komanduri KV; Pereira D; Goodman M; Jimenez AM; Beitinjaneh A; Wang TP; Lekakis LJ
Leuk Lymphoma; 2020 Apr; 61(4):940-943. PubMed ID: 31793821
[TBL] [Abstract][Full Text] [Related]
31. Impact of
Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
[TBL] [Abstract][Full Text] [Related]
32. The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
Nair R; Neelapu SS
Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399
[TBL] [Abstract][Full Text] [Related]
33. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy.
Chen PH; Lipschitz M; Weirather JL; Jacobson C; Armand P; Wright K; Hodi FS; Roberts ZJ; Sievers SA; Rossi J; Bot A; Go W; Rodig SJ
JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32484797
[TBL] [Abstract][Full Text] [Related]
34. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
[No Abstract] [Full Text] [Related]
35. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
36. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study.
Ram R; Grisariu S; Shargian-Alon L; Amit O; Bar-On Y; Stepensky P; Yeshurun M; Avni B; Hagin D; Perry C; Gurion R; Sarid N; Herishanu Y; Gold R; Glait-Santar C; Kay S; Avivi I
Haematologica; 2022 May; 107(5):1111-1118. PubMed ID: 34233446
[TBL] [Abstract][Full Text] [Related]
37. Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.
Byrne M; Oluwole OO; Savani B; Majhail NS; Hill BT; Locke FL
Biol Blood Marrow Transplant; 2019 Nov; 25(11):e344-e351. PubMed ID: 31279751
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
[TBL] [Abstract][Full Text] [Related]
39. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
St-Pierre F; Gordon LI
Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471
[TBL] [Abstract][Full Text] [Related]
40. Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas.
Johnson PC; Abramson JS
Leuk Lymphoma; 2020 Nov; 61(11):2561-2567. PubMed ID: 32611216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]